Dalpiciclib and hormone therapy for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 18 years or older, with known menopausal status (postmenopausal, premenopausal, or perimenopausal).
- You have a type of breast cancer called hormone receptor positive (HR+) and HER2-negative, confirmed by biopsy.
- Your cancer is early stage (IIA to IIIC) and has not spread to other parts of the body (stage IV or inflammatory breast cancer is excluded).
- You had surgery to remove the cancer, and it has been less than 12 months since that surgery.
- You are in generally good health, with an ECOG status of 0 or 1 (able to carry on normal activities or do light work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called dalpiciclib, a CDK4/6 inhibitor, given after surgery to lower the risk of breast cancer returning. It's for women with hormone-positive, HER2-negative early-stage breast cancer.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.